Anvisa Publishes Medicine Record for Disease that Affects Calcium Levels
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.4 Articles
4 Articles
Metrópoles
gazetaweb.comRemedy, which helps in the replacement of parathyroid hormone, is indicated for the treatment of adults with chronic hypoparathyroidism
Yorvipath replenishes parathyroid hormone and helps regulate calcium and phosphate levels in the body. Read on Power360.
The National Agency for Health Surveillance (Anvisa) published the registration of the drug Yorvipath (palopegteriparatide), parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In a note, the agency highlighted that the condition is rare, but treatable, causes low levels of calcium in the blood and is usually caused by damage to the parathyroid glands during surgeries, but can also be ca…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
